Itonis, Inc. Signs Facebook Ad Campaign for Its Emesyl Anti-Nausea Homeopathic Product in California Market

LAGUNA HILLS, CA--(Marketwired - September 20, 2016) - Itonis, Inc. (OTC PINK: ITNS) is pleased to announce that it has signed an agreement with Facebook to run online advertisements over a 30-day period in its California Market for its Emesyl® anti-nausea Homeopathic product.

The online advertisements have already started and are designed to target an audience within the state of California who suffer from nausea and nausea-like symptoms.

The Facebook advertisement can be viewed here: https://www.facebook.com/650869058317959/posts/1217313255006867

A "Shop Now" button links viewers to the https://www.Emesyl.com website for anyone wishing to purchase the Emesyl® anti-nausea product.

"The Facebook ad campaign is another step Itonis is moving forward to create additional branding and retail sales for our anti-nausea Emesyl® product," said Steve Pidliskey, Itonis Vice President.

About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyECheck's patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.

Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.